Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$7.0.

  • Karyopharm Therapeutics' EPS (Basic) fell 8766.76% to -$7.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.91, marking a year-over-year decrease of 7610.62%. This contributed to the annual value of -$17.93 for FY2025, which is 9054.2% down from last year.
  • Per Karyopharm Therapeutics' latest filing, its EPS (Basic) stood at -$7.0 for Q4 2025, which was down 8766.76% from -$3.82 recorded in Q3 2025.
  • Karyopharm Therapeutics' EPS (Basic)'s 5-year high stood at $2.26 during Q2 2024, with a 5-year trough of -$17.9 in Q4 2023.
  • Its 5-year average for EPS (Basic) is -$2.53, with a median of -$0.7 in 2021.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 416190.48% in 2023, then soared by 87931.03% in 2024.
  • Karyopharm Therapeutics' EPS (Basic) (Quarter) stood at $0.52 in 2021, then tumbled by 180.77% to -$0.42 in 2022, then plummeted by 4161.9% to -$17.9 in 2023, then soared by 79.16% to -$3.73 in 2024, then tumbled by 87.67% to -$7.0 in 2025.
  • Its EPS (Basic) stands at -$7.0 for Q4 2025, versus -$3.82 for Q3 2025 and -$4.32 for Q2 2025.